PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results

• Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently • Recruitment Progressing as Planned with A pproximately 900 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Soft Tissue